NASDAQ:ATHA

Athira Pharma Stock Forecast, Price & News

$10.06

+0.15 (+1.51 %)

(As of 08/3/2021 12:00 AM ET)

Add

Compare

Today's Range

$9.69

▼

$10.06

50-Day Range

$9.52

▼

$20.87

52-Week Range

$9.22

▼

$34.79

Volume302,153 shs

Average Volume752,439 shs

Market Capitalization$374.46 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive ATHA News and Ratings via Email

Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter.

About Athira Pharma

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Athira Pharma, Inc. (ATHA) Outpaces Stock Market Gains: What You Should Know
August 3, 2021 | finance.yahoo.com

CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Athira Pharma, Inc. Shareholders of Securities Fraud Class Action Lawsuit
August 3, 2021 | finance.yahoo.com

ATHIRA SHAREHOLDERS: August 24, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser
August 3, 2021 | finance.yahoo.com

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
August 3, 2021 | finance.yahoo.com

ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Athira Pharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities ...
August 2, 2021 | businesswire.com

ATHA Reminder: Kessler Topaz Meltzer & Check, LLP - Deadline Reminder for Athira Pharma, Inc. Investors
July 31, 2021 | finance.yahoo.com

Rosen, Global Investor Counsel, Encourages Athira Pharma, Inc. Investors to Secure Counsel Before Important August 24 Deadline in Securities Class Action - ATHA
July 31, 2021 | finance.yahoo.com

Investor Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc. (ATHA)
July 30, 2021 | finance.yahoo.com

Athira Pharma, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
July 30, 2021 | finance.yahoo.com

HAGENS BERMAN Reminds Athira Pharma (ATHA) Investors of Securities Class Action and Encourages Investors with Losses to Contact Firm's Attorneys
July 30, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATHA
Previous Symbol
CUSIPN/A
CIKN/A
Webathira.com
Phone206-221-8112
Employees20
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$8.44 per share
Price / Book1.19

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares37,223,000
Market Cap$374.46 million
Next Earnings Date8/12/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

2.20 out of 5 stars

Medical Sector

341st out of 1,309 stocks

Biological Products, Except Diagnostic Industry

51st out of 179 stocks

3.5 Analyst's Opinion

Consensus Rating
Athira Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $42.50, Athira Pharma has a forecasted upside of 322.5% from its current price of $10.06.
Amount of Analyst Coverage
Athira Pharma has received no research coverage in the past 90 days.

5.0 Community Rank

Outperform Votes
Athira Pharma has received 10 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Athira Pharma has received 3 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Athira Pharma has received 76.92% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Athira Pharma and other stocks. Vote “Outperform” if you believe ATHA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATHA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Athira Pharma does not currently pay a dividend.
Dividend Growth
Athira Pharma does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Athira Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
14.90% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
70.71% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Athira Pharma are expected to decrease in the coming year, from ($1.47) to ($2.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Athira Pharma is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Athira Pharma is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Athira Pharma has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Athira Pharma (NASDAQ:ATHA) Frequently Asked Questions

Is Athira Pharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Athira Pharma stock.
View analyst ratings for Athira Pharma or view top-rated stocks.

What stocks does MarketBeat like better than Athira Pharma?

Wall Street analysts have given Athira Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Athira Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Athira Pharma?

Athira Pharma saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 1,210,000 shares, a decrease of 28.4% from the June 15th total of 1,690,000 shares. Based on an average daily trading volume, of 1,120,000 shares, the days-to-cover ratio is presently 1.1 days. Approximately 3.6% of the company's stock are short sold.
View Athira Pharma's Short Interest.

When is Athira Pharma's next earnings date?

Athira Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Athira Pharma.

How were Athira Pharma's earnings last quarter?

Athira Pharma, Inc. (NASDAQ:ATHA) released its quarterly earnings results on Wednesday, May, 12th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.05.
View Athira Pharma's earnings history.

What price target have analysts set for ATHA?

4 brokerages have issued 12 month price objectives for Athira Pharma's stock. Their forecasts range from $30.00 to $53.00. On average, they anticipate Athira Pharma's stock price to reach $42.50 in the next twelve months. This suggests a possible upside of 322.5% from the stock's current price.
View analysts' price targets for Athira Pharma or view top-rated stocks among Wall Street analysts.

Who are Athira Pharma's key executives?

Athira Pharma's management team includes the following people:

Dr. Leen Kawas, CEO, Pres & Director (Age 35, Pay $706.47k)
Ms. Glenna K. Mileson, CFO & Corp. Sec. (Age 62, Pay $417.64k)
Dr. Hans Moebius, Chief Medical Officer (Age 64, Pay $425.06k)
Dr. Mark J. Litton M.B.A., Ph.D., MBA, Chief Operating Officer (Age 53)
Mr. Robert Renninger, Director of Accounting & Reporting
Ms. Rachel P. Lenington, CTO & Head of Product Devel. Strategy
Mr. Mark F. Worthington, Gen. Counsel
Dr. Kevin Church Ph.D., VP of Discovery (Age 36)

Who are some of Athira Pharma's key competitors?

Some companies that are related to Athira Pharma include Valneva (VALN), Ocugen (OCGN), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX), BioAtla (BCAB), Immunocore (IMCR), Krystal Biotech (KRYS), AlloVir (ALVR), ImmunityBio (IBRX), Monte Rosa Therapeutics (GLUE), Agenus (AGEN), Graphite Bio (GRPH), Vaxcyte (PCVX), Forma Therapeutics (FMTX) and Cullinan Oncology (CGEM).
View all of ATHA's competitors.

What other stocks do shareholders of Athira Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), The Boeing (BA), Alibaba Group (BABA), Beyond Meat (BYND), Delta Air Lines (DAL) and Extreme Networks (EXTR).

When did Athira Pharma IPO?

(ATHA) raised $160 million in an IPO on Friday, September 18th 2020. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Athira Pharma's stock symbol?

Athira Pharma trades on the NASDAQ under the ticker symbol "ATHA."

Who are Athira Pharma's major shareholders?

Athira Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Advisor Group Holdings Inc. (0.35%), Alliancebernstein L.P. (0.15%), Ieq Capital LLC (0.13%), Lindbrook Capital LLC (0.11%), New York State Common Retirement Fund (0.07%) and Rothschild Investment Corp IL (0.06%). Company insiders that own Athira Pharma stock include Joseph Edelman and Perceptive Advisors Llc.
View institutional ownership trends for Athira Pharma.

Which institutional investors are buying Athira Pharma stock?

ATHA stock was bought by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., Alliancebernstein L.P., Ieq Capital LLC, Rothschild Investment Corp IL, Lindbrook Capital LLC, Clear Creek Financial Management LLC, New York State Common Retirement Fund, and Cutler Group LP. Company insiders that have bought Athira Pharma stock in the last two years include Joseph Edelman, and Perceptive Advisors Llc.
View insider buying and selling activity for Athira Pharma or or view top insider-buying stocks.

How do I buy shares of Athira Pharma?

Shares of ATHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athira Pharma's stock price today?

One share of ATHA stock can currently be purchased for approximately $10.06.

How much money does Athira Pharma make?

Athira Pharma has a market capitalization of $374.46 million. The company earns $-19,950,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis.

How many employees does Athira Pharma have?

Athira Pharma employs 20 workers across the globe.

What is Athira Pharma's official website?

The official website for Athira Pharma is athira.com.

How can I contact Athira Pharma?

The company can be reached via phone at 206-221-8112 or via email at [email protected]

This page was last updated on 8/4/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here